CCDC7 and prostate carcinoma: These findings establish CCDC7<sub>19-13</sub> as a significant prognostic marker and potential therapeutic target in prostate cancer, with the recombinant CCDC7<sub>241aa</sub> protein offering promise for combination therapies in advanced cases.